文献速递慢阻肺

表面活性蛋白D是慢阻肺的因果保护因素:孟德尔随机化研究

Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation.
PubMed 文献 · Eur Respir J · 2017-11-30

结果显示,与血清SP-D水平升高相关的变异降低慢阻肺风险并减缓肺功能下降,提示SP-D升高对慢阻肺风险与进展具有因果保护作用。

要点

  • 血清SP-D水平升高与慢阻肺风险降低存在因果关联。
  • SP-D升高相关变异与肺功能下降减缓相关。
  • SP-D是慢阻肺有前景的生物标志物和治疗靶点。

核心结论

  • 遗传变异分析支持血清SP-D水平升高对慢阻肺风险和进展具有因果保护作用。

研究设计与样本

  • 在4061名慢阻肺患者中鉴定与血清SP-D水平相关的遗传变异。
  • 在1037人中评估这些变异对肺组织基因表达的影响。

主要发现

  • 染色体6(HLA区域)、10(SFTPD基因)和16(ATP2C2基因)三个区域与血清SP-D水平在全基因组显著性水平相关。
  • 与血清SP-D水平升高相关的变异降低慢阻肺风险(估计值-0.19,p=6.46×10-03)。
  • 与血清SP-D水平升高相关的变异减缓肺功能下降(估计值=0.0038,p=7.68×10-3)。

临床怎么用

  • SP-D可作为慢阻肺风险与进展评估的候选生物标志物。
  • SP-D是慢阻肺治疗开发的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surfactant protein D (SP-D) is produced primarily in the lung and is involved in regulating pulmonary surfactants, lipid homeostasis and innate immunity. Circulating SP-D levels in blood are associated with chronic obstructive pulmonary disease (COPD), although causality remains elusive.In 4061 subjects with COPD, we identified genetic variants associated with serum SP-D levels. We then determined whether these variants affected lung tissue gene expression in 1037 individuals. A Mendelian randomisation framework was then applied, whereby serum SP-D-associated variants were tested for association with COPD risk in 11 157 cases and 36 699 controls and with 11 years decline of lung function in the 4061 individuals.Three regions on chromosomes 6 (human leukocyte antigen region), 10 (SFTPD gene) and 16 (ATP2C2 gene) were associated with serum SP-D levels at genome-wide significance. In Mendelian randomisation analyses, variants associated with increased serum SP-D levels decreased the risk of COPD (estimate -0.19, p=6.46×10-03) and slowed the lung function decline (estimate=0.0038, p=7.68×10-3).Leveraging genetic variation effect on protein, lung gene expression and disease phenotypes provided novel insights into SP-D biology and established a causal link between increased SP-D levels and protection against COPD risk and progression. SP-D represents a very promising biomarker and therapeutic target for COPD.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Obeidat M, Li X, Burgess S, et al. Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. Eur Respir J. 2017. PMID: 29191953. doi:10.1183/13993003.00657-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。